312 related articles for article (PubMed ID: 33307512)
1. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
2. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
3. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
5. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
6. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
Cheng J; Zhou L; Liu Q; Tickner J; Tan Z; Li X; Liu M; Lin X; Wang T; Pavlos NJ; Zhao J; Xu J
J Cell Physiol; 2018 Mar; 233(3):2502-2512. PubMed ID: 28771720
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
Yin Z; Zhu W; Wu Q; Zhang Q; Guo S; Liu T; Li S; Chen X; Peng D; Ouyang Z
Eur J Pharmacol; 2019 Sep; 859():172550. PubMed ID: 31323222
[TBL] [Abstract][Full Text] [Related]
8. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis.
Chen X; Zhi X; Pan P; Cui J; Cao L; Weng W; Zhou Q; Wang L; Zhai X; Zhao Q; Hu H; Huang B; Su J
FASEB J; 2017 Nov; 31(11):4855-4865. PubMed ID: 28739641
[TBL] [Abstract][Full Text] [Related]
9. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
10. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
11. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
12. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
13. Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.
Wu YX; Sun Y; Ye YP; Zhang P; Guo JC; Huang JM; Jing XZ; Xiang W; Yu SY; Guo FJ
Mol Med Rep; 2017 Dec; 16(6):8200-8208. PubMed ID: 28983607
[TBL] [Abstract][Full Text] [Related]
14. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
[TBL] [Abstract][Full Text] [Related]
15. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
16. Asperosaponin VI protects against bone destructions in collagen induced arthritis by inhibiting osteoclastogenesis.
Liu K; Liu Y; Xu Y; Nandakumar KS; Tan H; He C; Dang W; Lin J; Zhou C
Phytomedicine; 2019 Oct; 63():153006. PubMed ID: 31299594
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.
Wen H; Liu Y; Li J; Wei D; Liu D; Zhao F
Clin Exp Rheumatol; 2018; 36(5):798-805. PubMed ID: 29465363
[TBL] [Abstract][Full Text] [Related]
18. Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.
Wu K; Lin TH; Liou HC; Lu DH; Chen YR; Fu WM; Yang RS
Osteoporos Int; 2013 Aug; 24(8):2201-14. PubMed ID: 23400250
[TBL] [Abstract][Full Text] [Related]
19. Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.
Cang D; Zou G; Yang C; Shen X; Li F; Wu Y; Ji B
J Pharmacol Sci; 2021 Aug; 146(4):206-215. PubMed ID: 34116734
[TBL] [Abstract][Full Text] [Related]
20. A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways.
Liu Y; Liu W; Yu Z; Zhang Y; Li Y; Xie D; Xie G; Fan L; He S
Cell Death Dis; 2021 Jun; 12(7):654. PubMed ID: 34175898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]